All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RES19-T
Therapeutic Area: Neurology Product Name: RES19-T
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Korys Investments
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 21, 2021
Details:
Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): RES19-T
Therapeutic Area: Neurology Product Name: RES19-T
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.